Key Developments: Horizon Pharma Inc (HZNP.O)

HZNP.O on Nasdaq

9.70USD
21 Aug 2014
Price Change (% chg)

$-0.16 (-1.62%)
Prev Close
$9.86
Open
$9.84
Day's High
$9.98
Day's Low
$9.53
Volume
644,825
Avg. Vol
2,066,737
52-wk High
$18.30
52-wk Low
$2.11

Search Stocks

Latest Key Developments (Source: Significant Developments)

Horizon Pharma Inc reiterates FY 2014 guidance; gives FY 2015 guidance; revenue guidance above analysts' estimates
Thursday, 7 Aug 2014 06:30am EDT 

Horizon Pharma Inc:Reiterates prior net sales guidance range for FY 2014 of $270 mln to $280 mln and adjusted EBITDA range of $80 mln to $90 mln.Provides preliminary net sales guidance for FY 2015 in range of $380 mln to $405 mln and preliminary adjusted EBITDA guidance of $150 mln to $170 mln.FY 2015 revenue of $352 mln and EBITDA of $163 mln - Thomson Reuters I/B/E/S.  Full Article

Horizon Pharma Inc announces execution of $300 mln senior secured credit agreement in connection with the proposed acquisition of Vidara
Thursday, 19 Jun 2014 07:00am EDT 

Horizon Pharma Inc:Entered into an agreement with group of lenders to provide Horizon with $300 mln in financing through five year senior secured credit facility.Funding is expected to occur coincident with closing of proposed acquisition of Vidara Therapeutics International Ltd.Agreement replaces $250 MLN bridge loan commitment received from Deerfield Management Company, L.P., which Company announced on March 19.Intends to use proceeds to effect proposed acquisition of Vidara, pay related transaction fees and expenses and for general corporate purposes.Citigroup Global Markets Inc. and Cowen and Company, LLC and their respective affiliates are acting as joint lead arrangers and initial lenders to Horizon for the financing.  Full Article

Horizon Pharma Inc announces Robert J. De Vaere to retire and names Paul W. Hoelscher Chief Financial Officer
Wednesday, 18 Jun 2014 07:00am EDT 

Horizon Pharma Inc:Robert J. De Vaere, its Chief Financial Officer, will retire on Sept. 30.Names Paul W. Hoelscher as Executive Vice President, Finance, effective June 23 and its Chief Financial Officer, effective Oct. 1.  Full Article

Horizon Pharma Inc updates FY 2014 revenue outlook above analysts' estimates; updates FY 2014 EBITDA outlook below analysts' estimates
Friday, 9 May 2014 06:30am EDT 

Horizon Pharma Inc:Expects FY 2014 net revenues in the range of $270 to $280 mln.Expects FY 2014 adjusted EBITDA (excluding Vidara acquisition related expenses, step up in inventory required under purchase accounting related to ACTIMMUNE and other potential special items or substantive events) to be in the range of $80 to $90 mln.FY 2014 revenue of $260 mln, EBITDA of $92 mln - Thomson Reuters I/B/E/S.  Full Article

Deerfield Provides up to $250 mln in acquisition financing to Horizon Pharma
Wednesday, 19 Mar 2014 07:15am EDT 

Deerfield Management Company:Provides up to $250 mln in acquisition financing to Horizon Pharma, Inc. for acquisition of Vidara Therapeutics International Ltd.Horizon Pharma has option to draw up to $250 mln in exchange for commitment fee.Amounts drawn will accrue interest payable quarterly in arrears and must be repaid within five years.  Full Article

Horizon Pharma Inc to Acquire Vidara Therapeutics International Ltd
Wednesday, 19 Mar 2014 07:00am EDT 

Horizon Pharma Inc:Says the company and Vidara Therapeutics International Ltd have entered into a definitive agreement under which Horizon Pharma will acquire Vidara through a reverse merger for stock and cash valued at about $660 million.Horizon Pharma plc will be the name of the resulting company.The proposed transaction has been unanimously approved by both companies' boards.Vidara will combine with Horizon with about 74 percent of Horizon's ordinary shares to be exchanged for Horizon's common shares, with Horizon surviving the merger.The shareholders of Vidara will retain about 26 percent of Horizon Pharma plc and receive $200 million in cash.  Full Article

Horizon Pharma Inc updates on FY 2014 outlook
Wednesday, 19 Mar 2014 07:00am EDT 

Horizon Pharma Inc:Expects FY 2014 pro forma combined revenues of $250 to $265 mln.Expects FY 2014 pro forma combined EBITDA of $65 to $75 mln.  Full Article

Horizon Pharma Inc reaffirms FY 2014 revenue outlook
Thursday, 13 Mar 2014 06:30am EDT 

Horizon Pharma Inc:Reaffirms FY 2014 net revenue of $190 to $205 mln.  Full Article

Horizon Pharma Inc issues Q4, FY 2013 revenue guidance above analysts' estimates
Wednesday, 29 Jan 2014 07:30am EST 

Horizon Pharma Inc:Expects Q4 2013 total net revenues in the range of $31.9-$32.4 mln.Expects FY 2013 total annual net revenues in the range of $79.5-$80.0 mln.Q4 2013 revenue of $27.3 mln - Thomson Reuters I/B/E/S.FY 2013 revenue of $75 mln - Thomson Reuters I/B/E/S.  Full Article

POZEN Inc Announces U.S. Rights For VIMOVO to Be Acquired by Horizon Pharma, Inc.'s Subsidiary And AstraZeneca AB
Tuesday, 19 Nov 2013 06:15am EST 

POZEN Inc announced that AstraZeneca AB and Horizon Pharma USA, Inc., a subsidiary of Horizon Pharma, Inc have entered into an agreement for Horizon to acquire the U.S. rights for VIMOVO (naproxen / esomeprazole magnesium) delayed release tablets. Under the terms of the agreement, POZEN will continue to receive a 10% royalty on Net Sales of products sold in the United States, with guaranteed annual minimum royalty payments of $5 million in 2014, and $7.5 million each year thereafter, provided that the patents owned by POZEN which cover VIMOVO are in effect and no generic forms of VIMOVO are on the market. Also under the agreement, Horizon has assumed AstraZeneca`s right to lead the on-going Paragraph IV litigation for VIMOVO and will assume all patent-related defense costs relating to such litigation, including reimbursement for a specified amount of the cost of counsel retained by POZEN. AstraZeneca will continue to have rights to commercialize VIMOVO outside of the United States.  Full Article

With eye on tax rates, Horizon Pharma buys Ireland's Vidara

- Horizon Pharma Inc said it would buy Dublin-based Vidara Therapeutics International Ltd in a reverse merger for $660 million, the latest U.S. company looking to benefit from Ireland's low corporate tax rates.

Search Stocks